1. Hospitalized male or non-pregnant female adult patient = 18 years of age at the time of enrollment with signed informed consent. 2. Patient with SARS-CoV-2 infection as determined by RT-PCR or other commercial or public health assay in any specimen taken = 4 days prior to randomization. Patient with a second SARS-CoV-2 episode after resolution of the initial infection may be enrolled if the infection is reconfirmed by RT-PCR and all other eligibility criteria are met. 3. Patient hospitalized, who are requiring supplemental oxygen via nasal cannula, non-invasive ventilation or high-flow oxygen to maintain peripheral oxygen saturation of at least 92% at time of Screening 4. Female patients of childbearing potential and male patients with female partner of childbearing potential must agree to use at least one primary form of contraception for the duration of the study (applicable methods will be determined by the site but may include barrier contraceptives [male condom, female condom or diaphragm with a spermicidal gel], abstinence, hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches or contraceptive rings] and intrauterine devices) .5. Ability to provide informed consent personally, or by a legally acceptable representative if the patient is unable to do so. 6. Patient is willing and able to comply with all required study visits and follow-up required by the protocol. 7. Patient must agree not to enroll in another study of an investigational agent prior to completion of Day 60 of study

1. Hospitalized male or non-pregnant female adult patient = 18 years of age at the time of enrollment with signed informed consent. 2. Patient with SARS-CoV-2 infection as determined by RT-PCR or other commercial or public health assay in any specimen taken = 4 days prior to randomization. Patient with a second SARS-CoV-2 episode after resolution of the initial infection may be enrolled if the infection is reconfirmed by RT-PCR and all other eligibility criteria are met. 3. Patient hospitalized, who are requiring supplemental oxygen via nasal cannula, non-invasive ventilation or high-flow oxygen to maintain peripheral oxygen saturation of at least 92% at time of Screening 4. Female patients of childbearing potential and male patients with female partner of childbearing potential must agree to use at least one primary form of contraception for the duration of the study (applicable methods will be determined by the site but may include barrier contraceptives [male condom, female condom or diaphragm with a spermicidal gel], abstinence, hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches or contraceptive rings] and intrauterine devices) .5. Ability to provide informed consent personally, or by a legally acceptable representative if the patient is unable to do so. 6. Patient is willing and able to comply with all required study visits and follow-up required by the protocol. 7. Patient must agree not to enroll in another study of an investigational agent prior to completion of Day 60 of study